Phase I/Ib Study of Crenolanib With Ramucirumab and Paclitaxel as Second Line Therapy for Advanced Esophagogastric Adenocarcinoma
Latest Information Update: 14 Mar 2022
At a glance
- Drugs Crenolanib (Primary) ; Paclitaxel; Ramucirumab
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AROG Pharmaceuticals
- 01 Feb 2022 Status changed from recruiting to discontinued as per results published in the Cancer Chemotherapy and Pharmacology
- 01 Feb 2022 Results published in the Cancer Chemotherapy and Pharmacology
- 01 Jul 2019 Planned End Date changed from 1 Apr 2019 to 1 Aug 2020.